Aktuellt
SENASTE
Redeye provides a brief comment on Scandion Oncology’s Q3 2021 report. PANTAX phase Ib top-line data was our primary expected catalyst for the stock during Q4, now delayed into Q2/Q3 2022. We believe the long-term investment case is still intact, with the PANTAX phase Ib delay merely representing a bump in the road that does not change the big picture in a major way. We see CORIST phase II part 2/3 top-line data as the primary catalyst that could induce a share price re-rating during the coming year.
LÄS MER
